Although intramuscular (i.m.) injection of DNA encoding glycoprotein D (gD) of bovine herpesvirus-1 (BHV-1) induces immune responses in cattle, this route of delivery is inefficient. Here we assessed three parameters that may enhance the efficacy of a gD DNA vaccine in cattle. First, the immune response generated by i.m. injected plasmid expressing a secreted form of gD (tgD) was determined and found to be very similar in magnitude to the response induced by gD-expressing plasmid. Secondly, gD-and tgD-expressing plasmids were administered by intradermal (i.d.) immunization, which resulted in a superior immune response to the secreted form, but no improvement in the response to the membrane-associated form. However, the form of gD used for immunization did not influence the immunoglobulin subtype, the ratio of antigenspecific IgG1 to IgG2 being approximately 4 : 1.
Introduction
Bovine herpesvirus-1 (BHV-1) is an important pathogen of cattle causing a variety of clinical disease manifestations, including rhinotracheitis, vulvovaginitis, abortions, conjunctivitis, encephalitis and generalized systemic infections (Gibbs & Rweyemamu, 1977) . Vaccination with conventionally produced live-attenuated or inactivated vaccines has been the predominant control strategy against BHV-1. However, these vaccines may cause immune suppression, abortions or clinical disease if insufficiently attenuated (van Drunen Littel-van den Hurk et al., 1993) . Killed vaccines may not provide complete protection, due to a low antigen load or loss of important epitopes during inactivation and generally are poor inducers of cellular immunity (Monaco, 1992) . Some of the inadequacies of The use of antigen-encoding DNA represents a new approach to vaccine development with the potential advantage of generating long-lasting cell-mediated and humoral immunity, because proteins expressed from the DNA constructs may enter MHC class I-as well as class II-restricted pathways. Indeed, administration of non-replicating plasmid DNA expression vectors has been demonstrated to result in protein expression in situ after intramuscular (i.m.) injection (Wolff et al., 1990) or particle bombardment (Tang et al., 1992) and to lead to the development of cellular and humoral immune responses, as well as protection from viral, bacterial and parasitic infections (reviewed in Donnelly et al., 1994 ; Whalen & Davies, 1995) .
Although immune responses have been induced in a number of larger species, such as rabbits (Davis et al., 1994) , S. van Drunen Littel-van den Hurk and others S. van Drunen Littel-van den Hurk and others ferrets , monkeys (Coney et al., 1994) , chimpanzees (Davis et al., 1996 ; Boyer et al., 1996) , cattle (Cox et al., 1993) , pigs (Monteil et al., 1996 ; Gerdts et al., 1997) , sheep (Rothel et al., 1997) and fish (Anderson et al., 1996) , most information on the efficacy of DNA immunization has been generated in mice (Ulmer et al., 1993 ; Zhu et al., 1993 ; Hoffman et al., 1994 ; Davis et al., 1993 Davis et al., , 1994 Lowrie et al., 1994 ; Xu & Liew, 1994 ; Xiang et al., 1995 ; Yokoyama et al., 1995 ; Major et al., 1995 ; . Experiments in laboratory animals such as mice may provide very useful information regarding the effect of antigen form and methods to modulate the immune response. However, it has been much easier to induce immune responses in mice than in most other species, especially by i.m. inoculation. Therefore, it is important to also use a more relevant animal model to address questions concerning dose, route and method of delivery, specific immune responses and modulation for specific diseases.
Previously, we demonstrated that low doses of the major glycoproteins of BHV-1, gB, gC and gD, induce protective immunity in cattle when formulated in an appropriate adjuvant (van Drunen Littel-van den Hurk et al., 1990) . Consequently, any one of these glycoproteins would be anticipated to induce protective immune responses when delivered and expressed from plasmid DNA. Intramuscular immunization with gB, gC or gD plasmid DNA indeed led to the development of a humoral immune response in mice (Cox et al., 1993) . Furthermore, antibody responses and partial protection were achieved in cattle after repeatedly administering plasmid DNA encoding gD, using i.m. delivery. However, it is not practical to administer more than two immunizations, so the present study was designed to improve the immune responses elicited in cattle, by using an alternative promoter, route of delivery and\or antigen form of gD.
BHV-1 gD is a membrane-associated protein, so limited amounts may be made in transfected cells in vivo. Secretion of a viral protein from the transfected cells might enhance the amount of antigen available for processing and presentation by antigen-presenting cells (APCs), as well as influence antigen presentation and the type of APCs involved. Thus, as a first approach to enhance immune induction, a plasmid encoding a truncated, secreted form of gD was generated and tested in cattle.
Secondly, although i.m. delivery of DNA in saline has been by far the most studied to date (Ulmer et al., 1993 ; Yangkauckas et al., 1993 ; Davis et al., 1993 Davis et al., , 1994 Xiang et al., 1995) , several additional routes and vehicles have been used to achieve immunization with DNA (Leibiger, 1991 ; Stribling et al., 1992 ; Tang et al., 1992 ; Eisenbraun et al., 1993 ; Zhu et al., 1993 ; Raz et al., 1994) . Intradermal (i.d.) delivery was selected as an alternative method to i.m. inoculation of cattle for two reasons. First, in cattle the transfection efficiency of skin cells may be higher than in muscle cells, because in species other than mice there is extensive connective tissue in the muscle, which may impede DNA diffusion and transfection. Secondly, in contrast to the relatively low immune surveillance in the muscle tissue, the skin has associated lymphoid tissue, comprising Langerhans cells (MHC II), dendritic cells (MHC II), keratinocytes (MHC I and II) and other immune cells, which makes it highly immunocompetent (Bos & Kapsenberg, 1993) .
Finally, in addition to the efficacy of transfection, the rate of transcription and translation of the encoded protein may be a determining factor for the efficiency of a DNA vaccine. As an approach to enhance the rate of transcription, we replaced the Rous sarcoma virus (RSV) long terminal repeat (LTR) with the human cytomegalovirus (HCMV) immediate early gene promoter with the first intron A (IA), which is known to give a high rate of transcription in most cells.
The results of this study demonstrate the induction of strong protective immunity in calves by i.d. immunization with a plasmid expressing the truncated, secreted form of gD under control of the HCMV\IA promoter.
Methods
Cells and viruses. Bovine viral diarrhoea virus-free Madin-Darby bovine kidney (MDBK) cells were cultured in minimal essential medium (MEM ; Gibco-BRL), supplemented with 10 % foetal bovine serum (FBS ; Gibco-BRL). The Cooper and 108 strains of BHV-1 were propagated in MDBK cells.
Plasmids. Plasmids pSLRSVgD and pSLRSVtgD were constructed by cloning the genes encoding gD and a truncated version of gD (tgD) into pSL301 (Invitrogen) under control of the RSV LTR and with an SV40 polyadenylation signal. The truncated version of gD was constructed by terminating the protein at amino acid 355 immediately upstream of the membrane anchor . To create the pSLIA vector, the HCMV\IA promoter and a bovine growth hormone terminator for transcription termination and polyadenylation were removed from the VCL1010 vector (Vical Inc.) and inserted into pSL301. Full-length and truncated forms of the gD gene were inserted into pSLIA, which generated plasmids pSLIAgD and pSLIAtgD. Control plasmids were pSLRSV0 and pSLIA0, which consisted of the respective vectors with eukaryotic control elements. The plasmids were amplified in transformed Escherichia coli (DH5α strain) and purified using anionexchange resins (Qiagen). After the concentrations were determined, the plasmids were stored at k20 mC. The A #'! \A #)! ratios were typically 1n8 or higher. Expression and cellular localization of the full-length and truncated forms of gD were confirmed in vitro after transfection of COS-7 cells with the respective plasmids.
Immunization and challenge. For both trials 6-to 7-month-old, BHV-1-negative calves were randomly allocated to vaccine groups. In trial I, groups of ten calves were immunized i.m. in the gluteal muscle with 1 mg of (1) pSLRSVgD, (2) pSLRSVtgD or (3) pSLRSV0. Three immunizations were given 2 months apart in 2 ml 0n85 % saline. The calves were bled at the time of immunization, as well as 4 weeks after each immunization. In trial II, groups of six calves were immunized i.d. in the ear with 500 µg of (1) pSLRSVtgD, (2) pSLIAgD, (3) pSLIAtgD or (4) pSLIA0. Two immunizations were given 3 weeks apart in 500 µl 0n85 % saline. The calves were bled at the time of immunization as well as 2 weeks after the second immunization. The calves of groups 2, 3 and 4 (trial II) were challenged with BHV-1 1 week later. Each calf was exposed for 4 min to an aerosol of 10( p.f.u.\ml of BHV-1 strain 108, which was generated by a Devilbis Nebulizer, model 65.
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Virus isolation. Nasal secretions were collected on days k3, 2, 4, 6, 8 and 10 post-challenge using tampons. Virus was recovered from the nasal fluids and quantified by plaque titration in microtitre plates with an antibody overlay as described (van Drunen Littel-van den Hurk et al., 1990) .
Clinical evaluation. Following challenge, calves were clinically evaluated for 10 days by the attending veterinarian, who was blind to the vaccine groups. Body weights and rectal temperatures were measured daily. In addition, animals were given a nasal score and a clinical score between 0 (normal) and 4 (severe). The clinical score was based on levels of depression, conjunctivitis and rhinitis. A sick score was determined based on rectal temperature, depression, conjunctivitis and rhinitis, where 0 l healthy animal ; 1 l mildly sick animal [febrile ( 40 mC)pclinical signs of IBR] ; 2 l moderately sick animal ; 3 l severely sick animal ; 4 l moribund animal, which would be euthanized.
ELISAs. Polystyrene microtitre plates (Immulon 2, Dynatech) were coated with affinity-purified gB, gD or tgD (van Drunen Littel-van den Hurk et al., 1990) and incubated with serially diluted bovine sera. Alkaline phosphatase (AP)-conjugated goat anti-bovine IgG (Kirkegaard and Perry) was used as the detecting antibody. The reaction was visualized with p-nitrophenyl phosphate (PNPP). Antibody isotypes were determined in an indirect ELISA using gD-coated plates and isotype-specific monoclonal antibodies (provided by K. Nielson, Animal Disease Research Institute, Nepean, ON, USA). Horseradish peroxidase (HRPO)-conjugated rabbit anti-mouse IgG (Boehringer Mannheim), followed by 2,2h-azino-di-(3-ethyl-benzthiazoline sulfonate(6)) (ABTS), was used for detection. To identify anti-DNA antibodies, polystyrene microtitre plates (Immulon 2, Dynatech) were coated with plasmid DNA, salmon sperm DNA or denatured salmon sperm DNA and incubated with serially diluted bovine sera or a DNA-specific monoclonal antibody derived from autoimmune NZB\NZW mice (Braun & Lee, 1986) . Biotinylated rabbit anti-mouse IgG (Zymed), followed by streptavidinconjugated AP (Gibco-BRL), were used for detection. The reaction was visualized with PNPP.
Neutralization test. The neutralization titres in the bovine sera were determined as previously described and expressed as the reciprocal of the highest dilution of antibody that caused a 50 % reduction of plaques relative to the virus control (van Drunen Littel-van den Hurk et al., 1990) .
PAGE and Western blot analysis. PAGE was carried out in 8n5% discontinuous denaturing gels under non-reducing conditions. After electrophoresis, viral proteins were transferred to nitrocellulose sheets in 25 mM Tris, 0n192 M glycine, 20 % methanol, pH 8n3. The nitrocellulose sheet was incubated with 3 % skim milk powder (Blotto) in 10 mM TrisHCl, 0n5 M NaCl, pH 7n5 (TBS), followed by incubation with bovine sera or gB-, gC-and gD-specific monoclonal antibody cocktails in TBS containing 1 % Blotto. Finally, the nitrocellulose sheet was incubated with AP-conjugated rabbit anti-bovine IgG (Kirkegaard and Perry) or rabbit anti-mouse IgG (Bio-Rad) and developed with 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) (Bio-Rad).
Proliferation assays. Bovine blood was collected into citratedextran and peripheral blood mononuclear cells (PBMC) were isolated on Ficoll-Paque PLUS (Pharmacia). PBMCs were dispensed at 3n5i10' cells\ml culture medium consisting of MEM (Gibco-BRL), 10 % FBS (Sigma), 2 mM -glutamine (Gibco-BRL), 50 µg\ml gentamycin and 5i10 −& mM 2-mercaptoethanol. Subsequently, 100 µl volumes were dispensed into the wells of microtitre plates. UV-irradiated BHV-1 at 5i10& p.f.u.\ml or purified gD at 1 µg\ml was added in a 100 µl volume to triplicate wells. After 4 days in culture the cells were pulsed with [methyl-$H]thymidine (Amersham). The cells were harvested 18 h later and thymidine uptake was measured by scintillation counting. Proliferative responses were calculated as the means of triplicate wells and expressed as stimulation index (SI ; counts per min in the presence of antigen\counts per min in the absence of antigen). A stimulation index of 2 is considered positive. ELISPOT. PBMCs were cultured for 24 h in the presence of 1 µg gD, washed twice and resuspended to the appropriate concentration in culture medium. Nitrocellulose plates (Millipore) were coated for 2 h at room temperature with a bovine IFN-γ-specific monoclonal antibody. Unbound antibody was removed and 100 µl of each cell suspension was added to triplicate wells. After an overnight incubation at 37 mC, the plates were incubated with rabbit serum specific for bovine IFN-γ for 2-4 h at room temperature. Subsequently, the plates were incubated for 2 h at room temperature with biotinylated rat anti-rabbit IgG (Zymed), followed by 2 h at room temperature with streptavidin-conjugated AP (Gibco-BRL). The spots were visualized with BCIP-NBT substrate. After 30-60 min at room temperature, the plates were washed in ddH # O and air-dried before counting the number of stained spots in the wells. IFN-γ-secreting cells were expressed as the number of spots per 1i10' cells.
Statistical analyses. All data were analysed with the aid of a statistical software program (STATISTIX for Windows version 1.0 ; Analytical Software). ELISA and neutralization titres were expressed as the log "! reciprocal of the endpoint. Differences between the vaccine groups were examined by one-way ANOVA. If the overall test for a treatment effect in ANOVA was significant, then means of the transformed variables were compared by Tukey's method. Nasal virus shedding (p.f.u.\ml) was coded as log "! . Since the values were not normally distributed, statistical analysis was performed on the ranks of the raw values. Differences were examined by one-way ANOVA at two time-points, day 6 (peak of virus shed) and day 10 (end of trial). The clinical data, including nasal and sickness score, temperature and weight change, were analysed using a one-way ANOVA on day 7, when all animals were still included, and on day 10, at the end of the trial.
Results

Effect of cellular localization of gD on the immune response after i.m. injection
Previously, we demonstrated that a plasmid encoding the membrane-anchored form of gD induced immunity in calves after several i.m. immunizations. As a first approach to improve on this immunization regime, a plasmid expressing a truncated, secreted form of gD under control of the RSV LTR promoter was compared to the gD-expressing plasmid. The plasmid backbone with the eukaryotic control elements, pSLRSV0, was included as control. After three i.m. immunizations all animals seroconverted, but the antibody titres were low (Table 1) . Subsequent immunizations did not result in further enhancement of the antibody response. There were no differences between the titres induced by the full-length and truncated forms of gD (P 0n05). The gD-specific antibodies did possess low antiviral activity as shown by neutralization ( Table 1) .
Effect of cellular localization and promoter strength on the gD-specific responses after i.d. injection
Since the antibody response in trial I was low even after several immunizations with either form of gD, a second ‡ gD-specific ELISA titres were expressed as the reciprocal of the highest dilution resulting in a reading of two standard deviations above the value of a standard, negative control serum. Values are geometric means. § Virus-neutalizing antibody titres were expressed as a 50 % endpoint using 100 p.f.u. of BHV-1. Values are geometric means. R Titres were determined 3 weeks after the first (Bl.1) and 2 weeks after the second (Bl.2) immunization.
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experiment was designed in which the promoter and the route of delivery were modified (trial II). Calves were immunized i.d. with plasmids expressing gD or tgD under control of the HCMV\IA promoter. In order to directly compare promoters, an additional group was immunized i.d. with pSLRSVtgD. All calves immunized with plasmid DNA encoding tgD seroconverted after one immunization, having significantly (P 0n05) higher gD-specific, virus-neutralizing antibody titres than the control animals ( Table 2 , Fig. 1 A, B) . Changing the route of delivery appeared to have a profound effect on the antibody titres induced by pSLRSVtgD, which were up to 10-fold higher after i.d. delivery than after i.m. injection. A comparison of tgD expression from plasmids containing the HCMV\IA or RSV LTR promoter showed that the titres induced by pSLIAtgD were only 2-to 3-fold higher ; however, the difference in neutralizing antibody titre was significant (P 0n05) after two immunizations. Although the group immunized with plasmid DNA encoding gD developed a low antibody response, the neutralizing antibody titres induced after two immunizations were significantly higher (P 0n05) than those elicited by the control plasmid. In general, the antibody isotypes followed the same pattern as the total antibody response, with tgD-expressing plasmid inducing significantly higher IgG1 and IgG2 titres than gD-expressing plasmid. All vaccines used in this trial induced both IgG1 and IgG2, with the ratio of IgG1 : IgG2 being approximately 4 : 1.
To determine the specificity of the immune response, ELISA titres to gB were determined. All animals vaccinated with gD-or tgD-expressing plasmid developed gD-specific, but no gB-specific antibody titres (Fig. 1 B, C) . Furthermore, when the sera were analysed in a Western blot assay, calves immunized with plasmids expressing gD or tgD reacted with gD, but not with any other viral protein (Fig. 1 D) , which confirms that the animals had not been accidentally exposed to wild-type virus.
One of the safety issues for calves immunized with plasmid DNA is the question whether they will make anti-DNA antibodies. However, when we analysed the sera from all vaccinated animals prior to the first immunization as well as 8 (trial I) or 2 (trial II) months afterwards, no DNA-specific antibodies were found in any of the plasmid-vaccinated animals.
Protection from challenge with BHV-1
As the pSLIAtgD plasmid-immunized calves developed a significant neutralizing antibody response, this group of animals, as well as the calves that were immunized with pSLIAgD or pSLIA0, were challenged with BHV-1. On the day of challenge, there was no difference in temperature between the groups, but the mean rectal temperature of the control group (pSLIA0) exceeded that of the vaccine groups (pSLIAgD and pSLIAtgD) for the rest of the trial (Fig. 2 A) . The differences between the group vaccinated with the tgD-encoding plasmid and the control group were significant (P 0n05) on day 7 post-challenge. A further, non-subjective assessment of morbidity is the extent of weight loss following BHV-1 challenge. It was clear that the animals in the control group lost more weight during the trial (18 %) than did the vaccine groups (5-6 %) (Fig. 2 B) . In comparison to the pSLIAgD-and pSLIA0-vaccinated calves, the pSLIAtgD-immunized animals experienced significantly lower weight loss (P 0n05) between days 0 and 7. Both vaccine groups lost less weight (P 0n01) than the control group between days 0 and 10.
Clinical evaluation of the calves demonstrated that all groups experienced increases in nasal score after challenge, with those for the control group increasing steadily until day 9 and those of the vaccine groups returning to near prechallenge values by the end of the trial (Fig. 2 C) . The control group had a significantly higher nasal score than did the pSLIAtgD-vaccinated group on day 7 (P 0n05) and a significantly higher score than both vaccine groups on day 10 (P 0n01). The sickness score for the pSLIAtgD-vaccinated group appeared to be generally lower than those for the pSLIAgD-and pSLIA0-immunized groups from day 4 onwards (Fig. 2 D) . Significant differences among the groups were present on day 7 (P 0n05) with the control group being clearly different from the pSLIAtgD group. The overall ANOVA test for differences between the three groups was significant on day 10 (P 0n05), but the Tukey's test for the comparison of the means was not.
Finally, the extent of virus shedding post-challenge was determined. Significant differences in the amount of virus shed were detected among the groups both on day 6 (P 0n05) and on day 10 (P 0n001) (Fig. 2 E) . Comparison of the means showed more virus being shed by the control group than by the two other groups (P 0n05). In contrast to the pSLIAtgDimmunized calves, which all survived the challenge, one-third of the calves in the pSLIAgD-vaccinated group and all of the animals in the control group died or had to be euthanized (Fig.  2 F) . In the groups vaccinated with tgD-or gD-encoding plasmid, animals had a strong anamnestic response (Fig. 1) .
Antigen-specific proliferation and cytokine production
In order to assess the presence of cellular immune responses, PBMCs from pSLIAgD-, pSLIAtgD-and pSLIA0-immunized calves were isolated from peripheral blood before and after challenge, and stimulated in vitro with gD or BHV-1. Antigenspecific responses were measured by cellular proliferation. As shown in Fig. 3 (A) , the calves that were immunized with pSLIAtgD developed significantly higher proliferative responses (P 0n05) than the calves in the pSLIAgD and pSLIA0 groups.
To further examine the cell-mediated immune responses induced by these immunogens, we assessed the production of IDG IFN-γ after challenge. Following in vitro re-stimulation with gD, significant numbers of IFN-γ-secreting cells were found in PBMCs from pSLIAtgD-immunized cattle, whereas no IFN-γ-secreting cells were detected in the PBMCs from the pSLIAgD and pSLIA0 groups (Fig. 3 B) , which correlates well with the proliferative responses.
Discussion
Although i.m. injection of DNA encoding gD induces immune responses in cattle, this method of vaccination is inefficient. Therefore, we examined several parameters that may enhance the efficacy of a DNA vaccine, including antigen form, route of delivery and promoter strength. The immune responses induced by i.m. injection remained low regardless of the antigen form used. In contrast, although changing the route of delivery had no effect on the responses to gD-expressing plasmid, strong immunity was elicited by i.d. inoculation of tgD-encoding plasmid. The effect of promoter strength on the immune response to tgD-expressing plasmid was minimal.
Several factors may contribute to the difference in responsiveness to i.d. injected gD-and tgD-expressing plasmid. If indeed the transfection efficiency in the skin is higher than in the muscle, which should result in higher levels of protein expression, this may be an advantage for tgD. In contrast, the cell-associated form of gD may be toxic for transfected cells (Tikoo et al., 1990) , so higher levels of gD production may be detrimental. Secondly, the enhanced immune surveillance in the skin may be an advantage for tgD from a viewpoint of antigen uptake and presentation, but it may also account for elevated levels of effector CTLs and NK cells, which may target and eliminate cells expressing membrane-associated gD, thereby reducing the amounts of gD produced. Further evaluation of i.d. administered plasmids encoding membraneanchored and secreted forms of antigens is required to determine whether this observation is specific for BHV-1 gD, or is a generalized phenomenon.
A few direct comparisons of plasmid-encoded membraneanchored and secreted proteins have been performed in mice, which also indicate that the form of antigen does not have an effect on the magnitude of the immune response generated by i.m. DNA immunization (Xiang et al., 1995 ; Cardoso et al., 1996 ; Chow et al., 1997 ; Lewis et al., 1997) . However, plasmid expressing membrane-anchored antigen induced primarily IgG2a, whereas plasmid encoding secreted antigen elicited mostly IgG1 (Cardoso et al., 1996 ; Lewis et al., 1997) . Presently, it is not clear why there may be a difference in the type of immune response to membrane-bound and secreted forms of antigen in i.m. vaccinated animals, but not in the magnitude. Muscle cells do not normally present antigens, since they express little if any class I or class II MHC molecules (Hohfeld & Engel, 1994) and essentially undetectable levels of costimulatory molecules. Thus, even if the muscle cells express the encoded protein following DNA immunization, induction of immunity may depend not on protein expression within the muscle cells, but rather upon the expression or uptake of the protein by specialized APCs. However, such cells are not abundant in muscle and, indeed, antigen production and subsequent events leading to an immune response may both occur outside the muscle (Torres et al., 1997) . Clarification of the role of muscle cells in transfection and subsequent induction of immunity may be required to explain any effects of antigen compartmentalization.
Studies in mice have demonstrated that muscle inoculation of DNA vaccines results in predominantly T H 1-type responses with concomitant production of IFN-γ and serum IgG2a, whereas epidermal gene gun immunization has yielded primarily T H 2-type immunity with production of IL-4 and IgG1 (Pertmer et al., 1996) . However, a recent study suggested that this difference in T cell subset is dependent on the method, saline injection vs gene gun inoculation, rather than the route of inoculation (Feltquate et al., 1997) . Although not extensively studied, the existence of T H 1 and T H 2 subsets of CD4 + T cells has also been postulated for cattle (Brown et al., 1994) . Analysis of the antibody isotype induced following i.d. immunization of cattle with tgD-encoding plasmid showed the presence of both IgG1 and IgG2 with a ratio of 4 : 1. This is in contrast to the antibody profile of tgD subunit vaccine-immunized animals, which have an IgG1 to IgG2 ratio of 50 : 1 (van Drunen Littel-van den . The isotype profile of the calves immunized with tgD-expressing plasmid is comparable to that found in BHV-1 hyperimmune sera and suggests that the T cells developed after i.d. immunization include both T H 1 and T H 2 subsets. Furthermore, antigen-specific proliferative responses were demonstrated in the pSLIAtgD-vaccinated group and IFN-γ was produced by activated PBMCs of this group, which is also indicative of a cellular, as well as humoral component, to the immune response.
Protection against virus challenge was induced in the calves immunized with the tgD-encoding plasmid, as shown by a significant reduction in weight loss, virus excretion, temperature response and clinical disease. No significant protection was observed in the animals vaccinated with the gD-expressing plasmid during the first 7 days post-challenge, which correlates with the lower level of immunity pre-challenge. However, most of the calves immunized with the pSLIAgD plasmid exhibited reduced temperature response, clinical disease, weight loss and virus shedding, specifically from day 8 postchallenge. Since the antibody levels in these animals were very low pre-challenge, this may be attributed to the strong anamnestic response in this group.
In conclusion, calves immunized twice i.d. with plasmid encoding a secreted form of gD under control of the strong HCMV\IA promoter developed a balanced and strong immune response, which provided protection from viral challenge. This observation holds great promise for the practical application of DNA vaccines in cattle. Furthermore, the fact that no anti-DNA antibodies were found in the sera of IDH calves that received several high doses of plasmid provides a level of confidence concerning the safe use of DNA as a vaccine in animals expected to have a longer lifespan than the typical laboratory animal. Further improvements in the level of immunity achieved by DNA vaccination of cattle are anticipated to come from co-administration of plasmids encoding additional protective antigens and\or immune regulatory molecules.
